Related Experiment Video
Updated: Aug 22, 2026

Experimental Analysis of Apoptotic Thymocyte Engulfment by Macrophages
Published on: May 24, 2019
Emerging non-apoptotic functions of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/Apo2L
Roberta Di Pietro1, Giorgio Zauli
1Dipartimento di Biomorfologia, Università G. d'Annunzio, Via dei Vestini, Chieti Scalo, Italy. r.dipietro@unich.it
Abstract:
Tumor necrosis factor (TNF) is a cytokine that mediates tumor necrosis. To date, 20 different members of the TNF super-family and 21 different receptors have been identified. All ligands of the TNF super-family have been found to activate transcription factor NF-kappa B and c-Jun kinase. Members of this family have diverse biological effects, including induction of apoptosis, promotion of cell survival, and regulation of the immune system and hematopoiesis. The current review focuses on the biological effects of TNF-related apoptosis-inducing ligand (TRAIL), a TNF super-family member which, a few years ago, generated considerable enthusiasm for its anticancer activity, not accompanied by general toxicity in most normal tissues and organs.
Insights
Tumor necrosis factor (TNF) is a cytokine involved in tumor necrosis. This review highlights TNF-related apoptosis-inducing ligand (TRAIL) and its promising anticancer activity with minimal toxicity to normal tissues.
Area of Science:
- Immunology
- Molecular Biology
- Oncology
Background:
- Tumor necrosis factor (TNF) superfamily comprises 20 ligands and 21 receptors.
- TNF superfamily ligands activate transcription factors NF-kappa B and c-Jun kinase.
- These ligands have diverse roles in apoptosis, cell survival, immunity, and hematopoiesis.
Purpose of the Study:
- To review the biological effects of TNF-related apoptosis-inducing ligand (TRAIL).
- To highlight TRAIL's potential as an anticancer agent.
- To discuss TRAIL's selective toxicity profile.
Main Methods:
- Literature review of studies on TNF superfamily and TRAIL.
- Analysis of TRAIL's mechanism of action.
- Evaluation of TRAIL's efficacy and toxicity in preclinical and clinical studies.
Main Results:
- TRAIL induces apoptosis in various cancer cells.
- TRAIL exhibits limited toxicity in most normal tissues.
- TRAIL's anticancer potential is significant.
Conclusions:
- TRAIL is a promising candidate for cancer therapy.
- TRAIL's selective action warrants further investigation.
- TRAIL represents a novel therapeutic strategy in oncology.
Related Concept Videos
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Apoptosis
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Cellular Injury V: Apoptosis and Autophagy
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized by phagocytes.
